Dr. Reddy's Laboratories Ltd
. announced the launch of Tobramycin Inhalation Solution, USP a therapeutic equivalent generic version of TOBI (tobramycin) Inhalation Solution, approved by the US Food and Drug Administration (USFDA).
The TOBI (tobramycin) Inhalation Solution brand and generic had US sales of approximately $97 million MAT for the most recent twelve months ending in April 2019 according to IQVIA Health.
Dr. Reddy's Tobramycin Inhalation Solution, USP is available in a 300 mg/5 ml, single-dose Ampule.
Dr Reddys Laboratories Ltd is currently trading at Rs2,545.15, up by Rs33.35 or 1.33% from its previous closing of Rs2,511.80 on the BSE. The scrip opened at Rs2,508 and has touched a high and low of Rs2,551 and Rs2,489.85 respectively.